Enzymatica Interim report Q2/2023: An exciting and important time ahead

Q2

H1

• Net sales reached SEK 8.8 (9.6) million.
• The operating result totaled SEK -11.2 (-15.9) million.
• Earnings per share, basic and diluted, were SEK -0.07 (-0.10).
• Cash flow from operating activities totaled SEK -9.5 (-21.5) million

• Net sales reached SEK 21.8 (13.8) million.
• The operating result totaled SEK -25.5 (-34.0) million.
• Earnings per share, basic and diluted, were SEK -0.16 (-0.22).
• Cash flow from operating activities totaled SEK -21.7 (-31.7) million

Significant events during the quarter

Significant events after the quarter

• No significant events were reported during the quarter.

• No significant events were reported after the end of the quarter. 

Other events during and after the quarter

• The University of Kent, UK, conducted a clinical study starting in November 2022 to investigate ColdZyme's effects in-vivo among elite athletes in endurance sports such as cycling and long-distance running. The results of the placebo-controlled, double-blind, and randomized study are expected in August 2023.
• The Medical University of Innsbruck, Austria, conducted an in vitro study during the second quarter to explore the effect of ColdZyme on human cells infected with influenza virus. The study results are expected in August 2023.